ImmunityBio, NantKwest dose first patient in novel Covid-19 vaccine candidate trial

This article was originally published here

NantKwest and ImmunityBio’s hAd5-Covid-19 is a novel Covid-19 vaccine candidate designed to target the inner nucleocapsid (N) and the outer spike (S) protein, as well as activate both

The post ImmunityBio, NantKwest dose first patient in novel Covid-19 vaccine candidate trial appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply